Interim results from the phase II COCOON trial showed that proactive skincare reduced dermatologic toxicity by 50% in patients receiving frontline treatment for EGFR-mutant non-small cell lung cancer, according to the study team led by Bishal Tiwari at Nassau University Medical Center. The trial is aimed at mitigating acneiform rash and other skin-related adverse events that can limit adherence to cancer therapy. COCOON tests an intervention strategy designed to prevent rather than react to common EGFR-inhibitor skin toxicities. As more EGFR-targeted regimens move into earlier lines, such supportive-care readouts are increasingly viewed as clinically relevant endpoints. For the oncology community, the interim magnitude of reduction signals a pragmatic, implementable approach that could influence how dermatologic burden is managed during active treatment.